<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420768</url>
  </required_header>
  <id_info>
    <org_study_id>IM025-006</org_study_id>
    <nct_id>NCT03420768</nct_id>
  </id_info>
  <brief_title>A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of experimental medication BMS-986263 in adult patients with advanced hepatic
      fibrosis (scar tissue in the liver caused by inflammation that is far on in progress) after
      the patient is cured of hepatitis C (an infection caused by a virus that attacks the liver
      and leads to inflammation).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Actual">May 28, 2019</completion_date>
  <primary_completion_date type="Actual">December 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with histological improvement in liver fibrosis based on liver biopsy</measure>
    <time_frame>Up to 169 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with greater than or equal to 15 percent decrease in liver stiffness as measured by magnetic resonance elastography (MRE)</measure>
    <time_frame>Up to 169 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1 BMS-986263 45mg weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 BMS-986263 90mg weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Placebo weekly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 BMS-986263 45mg every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 BMS-986263 90mg every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 BMS-986263 90mg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Placebo every 2 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986263</intervention_name>
    <description>Administered by intravenous (IV) infusion</description>
    <arm_group_label>Part 1 BMS-986263 45mg weekly</arm_group_label>
    <arm_group_label>Part 1 BMS-986263 90mg weekly</arm_group_label>
    <arm_group_label>Part 2 BMS-986263 45mg every 2 weeks</arm_group_label>
    <arm_group_label>Part 2 BMS-986263 90mg every 2 weeks</arm_group_label>
    <arm_group_label>Part 2 BMS-986263 90mg every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by intravenous (IV) infusion</description>
    <arm_group_label>Part 1 Placebo weekly</arm_group_label>
    <arm_group_label>Part 2 Placebo every 2 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Participants must provide documentation showing a sustained virologic response (SVR)
             for at least 1 year (52 weeks) prior to the date of screening (SVR is defined as a
             negative hepatitis C RNA greater than or equal to 12 weeks from the end of therapy)

          -  Participants must have METAVIR Stage 3 or 4 (or equivalent if using other
             classification; eg, Ishak)

        Exclusion Criteria:

          -  Other causes of liver disease (eg, alcoholic liver disease, HBV [serologically
             positive as determined using United States Centers for Disease Control and Prevention
             guidance for interpretation of hepatitis B serologic test results], autoimmune
             hepatitis, drug-induced hepatotoxicity, Wilson disease, iron overload,
             alpha-1-antitrypsin deficiency, NASH, hemochromatosis)

          -  Participants having liver diseases associated with infection with any other hepatitis
             virus

          -  Detectable HCV RNA at screening

          -  Child-Pugh score &gt; 6

          -  Model for End-Stage Liver Disease score &gt;12

          -  Evidence of HCC at screening based on alpha-fetoprotein (AFP) levels: AFP &gt; 100 ng/mL
             (&gt; 82.6 IU/mL) OR AFP ≥ 50 and ≤ 100 ng/mL (≥ 41.3 IU/mL and ≤ 82.6 IU/ mL) with liver
             ultrasound showing findings suspicious for HCC, or any imaging technique (eg, magnetic
             resonance imaging [MRI] or computed tomography; based on local assessment), or
             ultrasound

          -  Blood transfusion in the last 6 months prior to screening due to the risk of
             re-infection with HCV, HBV, HIV, etc

          -  Participant has any disease or condition which, in the opinion of the investigator,
             might compromise patient safety (eg, hematologic, cardiovascular, pulmonary, renal,
             gastrointestinal, hepatic, skeletal, central nervous system, or compliment-mediated
             disease); or other conditions that may interfere with the absorption, distribution,
             metabolism, or excretion of BMS 986263, or would place the participant at increased
             risk

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <disposition_first_submitted>December 9, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 11, 2019</disposition_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

